GMC Celebrates 25 Years Of The Denali
To commemorate the 25th anniversary of Denali, GMC is offering customers a special 25th Anniversary Denali Package available ...
ALS drugs from Denali, Calico come up short, marking more failures for Healey trial
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
These Stocks Are Moving the Most Today: Nvidia, Micron, Uber, FuboTV, Inari Medical, Denali Therapeutics, and More
Stock futures were rising modestly Tuesday, a day after tech shares helped lift the S&P 500 to its second straight gain.These ...
Fintel on MSN6h
Baird Initiates Coverage of Denali Therapeutics (DNLI) with Outperform Recommendation
Fintel reports that on January 7, 2025, Baird initiated coverage of Denali Therapeutics (NasdaqGS:DNLI) with a Outperform ...
On screen: Wampanoag character makes first appearance on PBS' national 'Molly of Denali'
Mashpee Wampanoag educator Kitty Hendricks-Miller (Nanaweetah), consults on PBS 'Molly of Denali' as Cape-based tribe debuts ...
Denali Water Solutions says stink in River Valley caused no ‘physical harm’
Fort Smith area plaintiffs have not shown they suffered physical harm from an intermittent but widespread offensive smell in ...
BioSpace5h
Denali Suffers Another ALS Fail With Phase II/III Flop
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data ...
Denali Therapeutics’ Phase II/III trial of ALS therapy fails to meet primary endpoint
The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.
clinicaltrialsarena3h
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trial
Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.
Denali Therapeutics' ALS drug fails in mid-to-late stage trial
Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal ...